Drug
Capecitabine Oral Product
Capecitabine Oral Product is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
active_not_recruiting125%
completed125%
recruiting250%
Recent Activity
3 active trials
Showing 4 of 4
active_not_recruitingphase_3
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986
recruitingphase_2
CapTemY90 for Grade 2/3 NET Liver Metastases
NCT04339036
recruitingphase_3
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298
completedphase_2
Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.
NCT03428529
Clinical Trials (4)
Showing 4 of 4 trials
NCT04639986Phase 3
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04339036Phase 2
CapTemY90 for Grade 2/3 NET Liver Metastases
NCT04263298Phase 3
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT03428529Phase 2
Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4